Applying to Clinical Trial: Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Contact this trialFirst, we need to learn more about you.

NMDA Receptor Antagonist

SLS-002 for Depression

Recruiting2 awardsPhase 2

Baltimore, Maryland

This trial is testing a nasal spray with ketamine to help adults with severe depression who are at risk of suicide. The spray works by quickly changing brain activity to improve mood and reduce suicidal thoughts. Esketamine, a form of ketamine, was approved to treat difficult-to-treat depression.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our